Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1 2Phase NA 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasms 13Carcinoma, Non-Small-Cell Lung 8Melanoma 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 3Lymphoma 3Solid Tumor 2Recurrence 2Lung Neoplasms 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Synovitis, Pigmented Villonodular 1Solid Tumours 1Solid Tumour 1Solid Tumors, KRAS Mutation 1Solid Tumors 1Solid Tumor, Adult 1Prostatic Neoplasms 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Radiotherapy 38Carboplatin 37pembrolizumab 36Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Magnetic Resonance Spectroscopy 16Cyclophosphamide 15osimertinib 14Irinotecan 13Etoposide 13Radiation 12Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 8Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Midazolam × Clear all
NCT04051827 2025-07-28

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Takeda

Phase 1 Completed
26 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03420742 2023-01-27

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Takeda

Phase 1 Completed
24 enrolled 17 charts
Thoracic

Carcinoma, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡